RBL1 and central nervous system cancer: In the signature, HDAC1 (HR:1.4938) and RBL1 (HR:1.7148) were deemed a hazard, while RUNX1T1 (HR:0.7349), FKBP3 (HR:0.6382), and PHF21A (HR:0.4956) promoted survival possibilities for glioma patients (Figure 10A).